The strong survival and safety data is a significant catalyst for DRTSW. Expect short-term volatility as the market digests the ASCO presentation. Monitor upcoming IMPACT and ACAPELLA trial updates for further de-risking. The company may need to raise capital for larger trials, so watch for potential dilution.
Price Chart
Executive Summary
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026. Median OS for second-line metastatic patients was 11.2 months vs historical ~4-6 months, with a favorable safety profile (no treatment-related deaths). The data de-risks the platform and supports advancement of the IMPACT trial.
Key Facts
- Pooled analysis of three Phase I/II studies in locally advanced or metastatic PDAC.
- Second-line metastatic mOS: 11.2 months from enrollment (historical ~4-6 months).
- Second-line locally advanced mOS: 11.1 months from enrollment (historical ~9 months).
- Third-line metastatic mOS: 7.9 months from enrollment (historical ~4-7 months).
- Treatment-associated AEs in 36% of subjects, Grade ≥3 in 9%, no treatment-related deaths.
- Data presented at 2026 ASCO Annual Meeting.
Financial Impact
Positive clinical data for a pre-revenue biotech; no financial figures disclosed.
Risk Factors
- Early-stage, non-randomized data with small sample size.
- Need for larger randomized trials to confirm efficacy.
- Company is pre-revenue and may require additional financing.
- Regulatory approval path uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063182 |
| Document: ea0292770-6k_alpha.htm | 0001213900-26-063182 |
| Document: 0001213900-26-063182-index-headers.html | 0001213900-26-063182 |
| Document: 0001213900-26-063182-index.html | 0001213900-26-063182 |
| Document: 0001213900-26-063182.txt | 0001213900-26-063182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access